Mitochondrial division inhibitor-1 treatment inhibits oxidative metabolism and thus lung cancer cell proliferation by mediating pathological ROS production and alterations in isocitrate dehydrogenase activity to reduce circulating levels of TCA. This evidence concerns the gene IDH3A and lung carcinoma.